+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5639599
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Nuclear Medicine Diagnostics Market is projected to reach USD 1.49 Billion in 2026. It is expected to continue growing at a CAGR of 13.17%, reaching USD 3.12 Billion by 2032.

Prostate cancer nuclear medicine diagnostics are moving from a specialist imaging option to a core clinical decision tool in oncology. The field is anchored by positron emission tomography and single-photon emission computed tomography used to localize disease, characterize recurrence, guide radioligand therapy eligibility, and improve confidence in staging. Demand is reinforced by the global prostate cancer burden; IARC GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases worldwide, making it one of the most frequently diagnosed cancers in men.

PSMA-targeted PET imaging has become the defining growth catalyst. Gallium-68 and fluorine-18 PSMA radiotracers have demonstrated higher lesion detection than conventional CT, bone scan, or older choline-based imaging in many clinical scenarios, particularly biochemical recurrence and high-risk primary staging. As guidelines from major oncology, urology, and nuclear medicine bodies increasingly recognize PSMA PET, healthcare systems are prioritizing cyclotron capacity, generator access, radiopharmacy networks, and integrated PET/CT workflows.

Transformative Shifts in the Diagnostic Landscape

The landscape is being reshaped by the transition from anatomy-led imaging to molecular, target-specific diagnostics. PSMA PET/CT is expanding because it can identify nodal, bone, and soft-tissue disease at low tumor burden, supporting earlier treatment decisions and more precise patient selection. Fluorine-18 tracers are also changing distribution economics because their longer half-life enables broader regional delivery than gallium-68 in many settings.

Another major shift is the diagnostic-therapeutic convergence between PSMA imaging and radioligand therapy. Nuclear medicine departments are increasingly positioned within prostate cancer tumor boards, where imaging results influence surgery, radiation planning, systemic therapy sequencing, and theranostic eligibility. This integration is pushing hospitals, imaging technology providers, and radiopharmaceutical developers to build scalable quality systems, standardized interpretation protocols, and resilient isotope supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to alter how prostate cancer nuclear medicine diagnostics are acquired, interpreted, and operationalized. AI-enabled reconstruction can reduce image noise and may support shorter scan times or lower administered activity when validated under local protocols. Computer-aided lesion detection, automated segmentation, SUV quantification, and whole-body tumor burden measurement are improving reproducibility in PSMA PET workflows.

The cumulative impact is strongest when AI connects imaging with clinical context. Radiomics and machine learning models are being evaluated to predict disease aggressiveness, therapy response, and progression risk by combining PET signal, CT or MRI features, PSA kinetics, Gleason score, and treatment history. Industry leaders should treat AI as a regulated clinical decision-support layer, requiring transparent validation, bias monitoring, cybersecurity controls, and integration with PACS, RIS, oncology information systems, and electronic health records.

Key Regional Insights Across Major Markets

North America remains a leading region for prostate cancer nuclear medicine diagnostics due to FDA-cleared PSMA PET agents, high PET/CT installed capacity, strong academic nuclear medicine programs, and established reimbursement pathways. The United States has accelerated adoption through multiple approved PSMA-targeted tracers, while Canada benefits from centralized cancer care networks and growing provincial access, although availability still varies by geography.

Europe is a mature and innovation-rich region, supported by early PSMA PET adoption, strong university hospital infrastructure, and coordinated clinical research. The European Union benefits from cross-border regulatory harmonization, while the United Kingdom, Germany, France, Italy, and Spain continue to expand evidence-based use in staging and recurrence. Asia-Pacific is one of the fastest-evolving opportunity areas, with Japan, Australia, South Korea, China, and India investing in PET capacity, cyclotron networks, and oncology diagnostics to address rising cancer demand and aging-population needs.

Latin America is gaining momentum through Brazil and Mexico, where major urban centers are adopting PET-based prostate cancer imaging despite uneven reimbursement and radiopharmaceutical access. The Middle East, particularly GCC health systems, is investing in premium oncology infrastructure, specialist hospitals, and medical tourism-ready diagnostics. Africa remains underpenetrated, with access concentrated in select centers such as South Africa and North African urban hubs, creating long-term demand for regional radiopharmacy development, workforce training, and public-private investment.

Key Group Insights for Strategic Market Prioritization

ASEAN is characterized by rapid healthcare modernization but uneven nuclear medicine capacity, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines moving at different speeds in PET/CT access, tracer supply, and reimbursement. The GCC is one of the most attractive high-investment clusters because Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman are expanding oncology centers, radiology infrastructure, and specialist medical workforce capacity.

The European Union offers a strong platform for standardized adoption because regulatory alignment, multicenter trials, and nuclear medicine society-led clinical practice norms support scalable PSMA PET implementation. BRICS markets combine large prostate cancer patient populations with diverse infrastructure maturity: China and India are expanding quickly, Brazil and Russia have regional centers of excellence, and South Africa provides an important gateway for African nuclear medicine development.

G7 countries represent the deepest commercial base, with high diagnostic spending, advanced PET infrastructure, and strong pharmaceutical innovation in the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. NATO countries add relevance through resilient medical isotope supply chains, radiological safety standards, interoperable health systems, and public-sector hospital networks that can influence procurement and emergency preparedness in nuclear medicine.

Key Country Insights for Prostate Cancer Imaging Demand

The United States is the most commercially advanced country for prostate cancer nuclear medicine diagnostics, supported by FDA approvals for PSMA PET agents, high clinical awareness, broad PET/CT availability, and strong private and public payer engagement. Canada is expanding access through cancer agency-led models and provincial pathways, while Mexico is developing demand in private hospital networks and major metropolitan centers. Brazil leads Latin American scale, with São Paulo and other large cities supporting advanced PET services.

In Europe, the United Kingdom is strengthening PSMA PET use through specialist cancer pathways, Germany remains a global leader in nuclear medicine research and theranostics, and France benefits from sophisticated academic hospital networks. Italy and Spain continue to increase utilization in recurrence and staging, while Russia maintains PET infrastructure in major cities despite broader market constraints.

China is expanding PET/CT capacity and domestic radiopharmaceutical capabilities, while India offers high-volume long-term potential as oncology infrastructure grows beyond major cities. Japan benefits from advanced imaging quality standards and aging-population demand, Australia is a strong early adopter of PSMA PET evidence generation, and South Korea combines high technology adoption with sophisticated hospital systems and strong oncology diagnostics capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize scalable radiopharmaceutical access, including diversified isotope sourcing, validated cold-chain logistics, and partnerships with cyclotron operators, generator suppliers, and regional radiopharmacies. Commercial success increasingly depends on reliable same-day availability, standardized quality control, radiation safety compliance, and clear scheduling integration with PET/CT departments.

Providers and manufacturers should build evidence packages that connect PSMA PET results to measurable outcomes such as reduced unnecessary procedures, improved radiation planning, earlier recurrence detection, and better selection for radioligand therapy. Organizations should also invest in clinician education for urologists, radiation oncologists, medical oncologists, and nuclear medicine physicians to accelerate appropriate referrals.

Technology providers should embed AI-enabled quantification, structured reporting, and interoperability into imaging platforms while ensuring compliance with medical device regulations and data privacy rules. Market entrants should tailor pricing, reimbursement, and distribution strategies by country maturity rather than applying a single global launch model.

Research Methodology and Evidence Framework

This executive summary is based on triangulated secondary research and market intelligence methods suitable for healthcare technology and radiopharmaceutical analysis. The evidence base includes publicly available regulatory records, oncology and nuclear medicine guidelines, peer-reviewed clinical literature, cancer epidemiology databases, government health statistics, reimbursement references, and radiopharmaceutical access indicators.

Data validation relies on cross-checking clinical adoption signals against tracer approvals, PET infrastructure availability, radiopharmacy capabilities, guideline inclusion, and regional oncology investment trends. Qualitative interpretation is supported by analysis of hospital workflow requirements, isotope logistics, competitive positioning, payer considerations, and regulatory requirements. Findings are framed to support strategic planning and should be periodically updated as approvals, reimbursement policies, and clinical evidence evolve.

Conclusion and Strategic Outlook

Prostate cancer nuclear medicine diagnostics are entering a sustained expansion phase driven by PSMA-targeted imaging, growing PET infrastructure, radiotheranostic integration, and rising demand for precision oncology. The sector is no longer defined only by scan volume; it is increasingly shaped by tracer logistics, evidence-based clinical pathways, quantitative imaging, and multidisciplinary adoption.

Organizations that combine dependable radiopharmaceutical supply, regulatory-grade data, AI-enabled workflow efficiency, and region-specific commercialization will be best positioned to capture value. As prostate cancer care shifts toward earlier detection of actionable disease and better treatment personalization, nuclear medicine diagnostics will remain a strategic pillar of the global oncology ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical
7.1. Introduction
7.2. 11C Choline
7.3. 18F DcfpyL
7.4. 18F Fluciclovine
7.5. 68Ga Psma
7.6. Emerging Agents
7.6.1. 18F Psma 1007
7.6.2. 64Cu Psma
8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality
8.1. Introduction
8.2. Pet
8.2.1. Digital Pet
8.2.2. Time Of Flight Pet
8.3. Spect
8.3.1. Conventional Spect
8.3.2. Spect Ct
9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication
9.1. Introduction
9.2. Biochemical Recurrence Detection
9.3. Initial Staging
9.4. Treatment Monitoring
10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User
10.1. Introduction
10.2. Academic Research Institute
10.3. Diagnostic Center
10.4. Hospital
11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Bayer AG
15.2. Blue Earth Diagnostics Ltd.
15.3. Cardinal Health, Inc.
15.4. Curium Pharma
15.5. Eckert & Ziegler SE
15.6. GE HealthCare Technologies Inc.
15.7. IBA Radiopharma Solutions
15.8. Jubilant Pharmova Limited
15.9. Lantheus Holdings, Inc.
15.10. Novartis AG
15.11. Siemens Healthineers AG
15.12. Telix Pharmaceuticals Limited
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL 11C CHOLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL 11C CHOLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL 11C CHOLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL 18F DCFPYL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL 18F DCFPYL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL 18F DCFPYL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL 68GA PSMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL 68GA PSMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL 68GA PSMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL EMERGING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL EMERGING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL EMERGING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL 18F PSMA 1007 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL 18F PSMA 1007 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL 18F PSMA 1007 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL 64CU PSMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL 64CU PSMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL 64CU PSMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL DIGITAL PET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL DIGITAL PET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL DIGITAL PET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SPECT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SPECT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SPECT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SPECT CT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SPECT CT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SPECT CT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INITIAL STAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INITIAL STAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INITIAL STAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 75. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 81. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 83. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 84. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 85. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 89. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 91. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 92. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 93. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 94. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 95. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 99. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 100. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 107. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 108. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 109. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 110. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 111. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 112. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 116. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 117. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 118. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 119. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 120. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 121. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 124. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 125. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 126. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 127. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 128. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 129. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 138. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 140. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 141. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 142. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 143. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 144. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 145. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 148. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 149. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 150. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 151. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 152. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 153. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 156. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 157. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 158. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 159. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 160. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 161. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 172. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 173. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 174. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 175. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 176. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 177. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 178. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 180. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 181. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 182. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 183. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 184. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 185. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 186. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 189. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 190. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 196. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 197. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 204. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 205. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 206. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 207. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 208. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 209. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 210. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 212. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 213. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 214. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 215. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 216. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 217. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 218. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 221. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 222. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 224. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 229. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 230. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 231. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 232. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 233. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 234. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 237. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 238. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 239. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 240. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 241. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 242. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 245. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 246. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 247. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 248. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 249. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 250. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 253. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 254. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 255. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 256. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 257. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 261. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 262. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 263. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 264. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 265. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 266. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 269. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2017-2032 (USD MILLION)
TABLE 277. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2017-2032 (USD MILLION)
TABLE 278. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2017-2032 (USD MILLION)
TABLE 280. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 284. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Bayer AG
  • Blue Earth Diagnostics Ltd.
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler SE
  • GE HealthCare Technologies Inc.
  • IBA Radiopharma Solutions
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.12 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026 - Product Image

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Nuclear Medicine Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Radiopharmaceutical Supply Chain Market - Strategic Insights and Forecasts (2026-2031) - Product Image

Radiopharmaceutical Supply Chain Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 156 Pages
  • Global
From
Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034 - Product Image

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From

About the Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate cancer nuclear medicine diagnostics is a segment within the broader field of medical diagnostics focused on using nuclear medicine techniques to detect and evaluate prostate cancer. Nuclear medicine is a medical specialty that employs small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and sometimes treat diseases. In prostate cancer diagnosis, these radiopharmaceuticals are designed to target specific molecules associated with the presence of cancer cells, such as the prostate-specific membrane antigen (PSMA). Imaging technologies like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are utilized in conjunction with these radiotracers to visualize the distribution of the radioactive material within the prostate gland and surrounding tissues. This enables physicians to detect the presence and extent of prostate cancer, thereby guiding treatment decisions and prognostication. Key players in the prostate cancer nuclear medicine diagnostics market include companies that specialize in the production of radiopharmaceuticals, as well as those that manufacture the imaging equipment used in the diagnostic process. Some prominent companies in this market are Advanced Accelerator Applications (a subsidiary of Novartis), Blue Earth Diagnostics (a Bracco company), Progenics Pharmaceuticals (part of Lantheus Medical Imaging), IsoRay Medical, and Bayer AG. These companies engage in research and development to improve the specificity and sensitivity of nuclear diagnostic agents for prostate cancer and strive to create advanced imaging systems for more precise disease characterization. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.